Sotera Health (NYSE:SHC) Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Sotera Health (NYSE:SHC) from a buy rating to a hold rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “Sotera Health Company is a provider of mission-critical end-to-end sterilization solutions and lab testing as well as advisory services for the healthcare industry. The company market through businesses which include Sterigenics(R), Nordion(R) and Nelson Labs(R). Sotera Health Company is Sotera Health Company is based in CLEVELAND. “

Separately, Barclays raised their price target on shares of Sotera Health from $30.00 to $32.00 and gave the stock an overweight rating in a research report on Friday, August 13th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Sotera Health currently has an average rating of Buy and a consensus target price of $32.14.

SHC opened at $25.51 on Wednesday. Sotera Health has a 12-month low of $21.21 and a 12-month high of $30.38. The company has a current ratio of 2.70, a quick ratio of 2.46 and a debt-to-equity ratio of 3.58. The firm has a market capitalization of $7.22 billion and a PE ratio of 67.13. The firm has a 50 day moving average of $24.94 and a two-hundred day moving average of $24.50.

Sotera Health (NYSE:SHC) last posted its quarterly earnings results on Thursday, August 12th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.07. The business had revenue of $251.92 million for the quarter, compared to analysts’ expectations of $226.27 million. As a group, analysts predict that Sotera Health will post 0.85 EPS for the current fiscal year.

In related news, insider Michael P. Rutz sold 67,000 shares of Sotera Health stock in a transaction on Wednesday, August 25th. The shares were sold at an average price of $25.03, for a total value of $1,677,010.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 64.95% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in SHC. Alliancebernstein L.P. acquired a new stake in Sotera Health in the 1st quarter valued at $738,000. Rhumbline Advisers acquired a new stake in Sotera Health in the 1st quarter valued at $1,264,000. American International Group Inc. acquired a new stake in Sotera Health in the 1st quarter valued at $34,000. New York State Common Retirement Fund acquired a new stake in Sotera Health in the 1st quarter valued at $1,310,000. Finally, Acadian Asset Management LLC acquired a new stake in Sotera Health in the 1st quarter valued at $145,000. 86.69% of the stock is currently owned by hedge funds and other institutional investors.

Sotera Health Company Profile

Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the Americas, Europe and Asia. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries.

Read More: How Do You Make Money With Penny Stocks?

Get a free copy of the Zacks research report on Sotera Health (SHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Sotera Health (NYSE:SHC)

Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.